Finnberg Niklas, Gokare Prashanth, El-Deiry Wafik S
Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Curr Clin Pharmacol. 2015;10(4):279-98. doi: 10.2174/1574884710666151020095911.
The survival rate of patients with colorectal cancer (CRC) is steadily increasing over the past decade. However, CRC continue to be one of the leading causes of cancer-related fatality in the United States. Current targeted strategies offer limited clinical benefits and the overall survival rate for CRC remains low. Improved understanding of the molecular changes associated with CRC that control growth factor signaling and evasion of cell death allow for the development of improved targeted therapy. This review aims to discuss some of the emerging therapies aimed to target CRC.
在过去十年中，结直肠癌（CRC）患者的生存率稳步上升。然而，在美国，CRC仍然是癌症相关死亡的主要原因之一。目前的靶向治疗策略临床获益有限，CRC的总体生存率仍然较低。对与CRC相关的分子变化有了更深入的了解，这些变化控制着生长因子信号传导和细胞死亡逃逸，从而推动了改进的靶向治疗的发展。本综述旨在讨论一些针对CRC的新兴疗法。
